8.60
-0.92%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioMaxima
Its shares trade on GPW under the ticker BMX.WA. It has been listed since 8 June 2010. In the fiscal year to 31 December 2025, it reported revenue of PLN 60.9m and net income of PLN 105,000. At that date it held total assets of PLN 77.5m and shareholders' equity of PLN 48.1m.
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Jun 2010
- Website
- biomaxima.com ↗
Leadership
Pay as last reported
- Mr. Rafal JelonekChairman of the Supervisory Board
- Mr. Lukasz UrbanChairman of the Management Board
- Mr. Krzysztof MikoszVice Chairman of the Supervisory Board
- Mr. Henryk LewczukVice Chairman of the Management Board
- Ms. Zaneta HomendaChief Accountant
- Mr. Piotr JanowskiMember of the Management Board, since 2018
- Mr. Andrzej MikoszMember of the Management Board, since 2021
- Mr. Michal JanikMember of the Supervisory Board
- Mr. Kacper KrysiakMember of the Supervisory Board
- Mr. Tomasz LiberaMember of the Supervisory Board
- Mr. Miroslaw PanekMember of the Supervisory Board
- Mr. Artur WojcieszukMember of the Supervisory Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates in biotechnology and laboratory diagnostics with headquarters in Lublin, Poland.
- Manufactures and distributes reagents and equipment for laboratory diagnosis.
- Supplies hospitals and laboratories in multiple countries including Poland, Lithuania, Latvia, Romania, and France.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market share provided.
- No information on competitive advantages or unique technologies.
Opportunities
- Expansion into new markets beyond current countries of operation.
- Potential for increased demand in diagnostic reagents and equipment.
- Opportunity to leverage merger with Cebo Sp z o o for growth.
Threats
- Dependence on specific markets such as Poland, Lithuania, Latvia, Romania, and France.
- Competition in the biotechnology and laboratory diagnostics sector.
- Risk of regulatory changes affecting the healthcare industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.